Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02163213 · ClinicalTrials.gov registry record · NA
Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g Bid on Nutritional Status in Subjects With IBS-D
A NA study of Diarrhea-Predominant Irritable Bowel Syndrome, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT02163213 is a NA study of Diarrhea-Predominant Irritable Bowel Syndrome that has completed, run by Mayo Clinic. The registered enrollment target is 15 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02163213, a NA study of Diarrhea-Predominant Irritable Bowel Syndrome, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the safety and effectiveness of oral nutritional therapy Serum-Derived Bovine Immunoglobulin (SBI) on nutritional status, epithelial barrier function, and mucosal expression of pivotal genes including tight junction, secretory mechanisms, tissue repair proteins and chemokines in subjects with IBS-D.
Conditions Studied
Interventions
- OTHER Serum-derived bovine immunoglobulin protein isolate (SBI)
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-06 |
| Est. Completion | 2016-11-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02163213
The ClinicalTrials.gov registry entry for NCT02163213 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diarrhea-Predominant Irritable Bowel Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Serum-derived bovine immunoglobulin protein isolate (SBI) is the first listed.
NCT02163213 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT02163213 about?
NCT02163213 is a clinical study titled "Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g Bid on Nutritional Status in Subjects With IBS-D". To evaluate the safety and effectiveness of oral nutritional therapy Serum-Derived Bovine Immunoglobulin (SBI) on nutritional status, epithelial barrier function, and mucosal expression of pivotal genes including tight junction, secretory mechanisms, tissue repair proteins and chemokines in subjects...
What is the current status of trial NCT02163213?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2014-06. Estimated completion is 2016-11-02.
What conditions does trial NCT02163213 study?
This clinical trial studies the following conditions: Diarrhea-Predominant Irritable Bowel Syndrome.
What interventions are being tested in trial NCT02163213?
The interventions under investigation include: Serum-derived bovine immunoglobulin protein isolate (SBI) (OTHER).
Who is sponsoring clinical trial NCT02163213?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02163213 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diarrhea-Predominant Irritable Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.